ANBL1531 (Pediatric Neuroblastoma)

What is the Purpose of this Study?

If you choose to be in this study, you will:
- Be randomized (like drawing numbers out of a hat) to get either
-- Group 1: Standard of care treatment; OR
-- Group 2: Study drug 131I-MIBG and standard of care treatment; OR
-- Group 3: Study drug 131I-MIBG and one stem cell transplant and standard of care chemotherapy; OR
-- Group 4: Standard of care treatment; OR
-- Group 5: Study drug Crizotinib plus standard of care treatment
- Have a scan and have tissue taken from your tumor sent for a test to see if it contains a specific gene
- Have standard treatment called induction therapy
What is the Condition Being Studied?
Newly Diagnosed High-Risk Neuroblastoma

Who Can Participate in this Study?

Children and Adults with Neuroblastoma who:

- Are 1 year old and less than 30 years old

- Are able to tolerate peripheral blood stem cell collection

Age Group
Both
Participating Institutions

What is Involved?

We are doing this study to find out if we can improve the treatment for patients with high-risk neuroblastoma by adding the study drug 131I-MIBG (131I-metaiodobenzylguanidine) or the study drug crizotinib to the standard treatment.

Study Details

Full Title
ANBL1531: A Phase 3 Study of 131 I-Metaiodobenzylguanidine (131 I-MIBG) or Crizotinib Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (NBL)
Principal Investigator

Protocol Number
IRB:
PRO00100226

NCT:
NCT03126916
ClinicalTrials.gov
View on ClinicalTrials.gov